Maternal and Fetal Health Research Centre, Division of Developmental Biology & Medicine, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Front Cell Infect Microbiol. 2020 Jul 30;10:389. doi: 10.3389/fcimb.2020.00389. eCollection 2020.
Chronic hypertension during gestation is associated with an increased risk of adverse pregnancy outcomes including pre-eclampsia, fetal growth restriction and preterm birth. Research into new chemotherapeutic regimes for the treatment of hypertension in pregnancy is limited due to concerns about fetal toxicity and teratogenicity, and new therapeutic avenues are being sought in alternative physiological pathways. Historically, generation of the vasodilator nitric oxide was believed to be solely from -arginine by means of nitric oxide synthase enzymes. Recently, a novel pathway for the reduction of dietary inorganic nitrate to nitrite by the bacteria in the oral cavity and subsequently to vasodilatory nitric oxide within the body has been uncovered. Dietary nitrate is abundant in green leafy vegetables, including beetroot and spinach, and reduction of exogenous nitrate to nitrite by oral bacteria can increase nitric oxide in the vasculature, lessening hypertension. Supplements rich in nitrate may be an attractive choice for treatment due to fewer side effects than drugs that are currently used to treat hypertensive pregnancy disorders. Additionally, manipulation of the composition of the oral microbiota using pro- and prebiotics in tandem with additional dietary interventions to promote cardiovascular health during gestation may offer a safe and effective means of treating hypertensive pregnancy disorders including gestational hypertension and pre-eclampsia. The use of dietary inorganic nitrate as a supplement during pregnancy requires further exploration and large scale studies before it may be considered as part of a treatment regime. The aim of this article is to review the current evidence that oral microbiota plays a role in hypertensive pregnancies and whether it could be manipulated to improve patient outcomes.
慢性妊娠高血压与不良妊娠结局风险增加相关,包括子痫前期、胎儿生长受限和早产。由于担心胎儿毒性和致畸性,针对妊娠高血压的新化疗方案的研究受到限制,因此正在寻求替代生理途径的新治疗途径。历史上,血管舒张一氧化氮的产生被认为仅来自 -精氨酸通过一氧化氮合酶。最近,一种新的途径被发现,即口腔中的细菌将膳食中的无机硝酸盐还原为亚硝酸盐,然后在体内转化为血管舒张性一氧化氮。膳食硝酸盐在绿叶蔬菜中含量丰富,包括甜菜根和菠菜,口腔细菌将外源性硝酸盐还原为亚硝酸盐可以增加血管中的一氧化氮,从而减轻高血压。富含硝酸盐的补充剂可能是一种有吸引力的治疗选择,因为它们的副作用比目前用于治疗妊娠高血压疾病的药物少。此外,通过使用益生菌和益生元来同时操纵口腔微生物组的组成,并结合其他饮食干预措施来促进妊娠期间的心血管健康,可能提供一种安全有效的治疗妊娠高血压疾病(包括妊娠期高血压和子痫前期)的方法。在将膳食无机硝酸盐用作补充剂用于妊娠之前,需要进一步探索和进行大规模研究,然后才能考虑将其作为治疗方案的一部分。本文的目的是综述口腔微生物组在妊娠高血压中的作用的现有证据,以及是否可以操纵它以改善患者的结局。